Table of Contents
1 Research Methodology and Statistical Scope
1.1 Market Definition and Statistical Scope of Cancer Minimal Residual Disease Testing
1.2 Key Market Segments
1.2.1 Cancer Minimal Residual Disease Testing Segment by Type
1.2.2 Cancer Minimal Residual Disease Testing Segment by Application
1.3 Methodology & Sources of Information
1.3.1 Research Methodology
1.3.2 Research Process
1.3.3 Market Breakdown and Data Triangulation
1.3.4 Base Year
1.3.5 Report Assumptions & Caveats
2 Cancer Minimal Residual Disease Testing Market Overview
2.1 Global Market Overview
2.1.1 Global Cancer Minimal Residual Disease Testing Market Size (M USD) Estimates and Forecasts (2019-2032)
2.1.2 Global Cancer Minimal Residual Disease Testing Sales Estimates and Forecasts (2019-2032)
2.2 Market Segment Executive Summary
2.3 Global Market Size by Region
3 Cancer Minimal Residual Disease Testing Market Competitive Landscape
3.1 Global Cancer Minimal Residual Disease Testing Sales by Manufacturers (2019-2025)
3.2 Global Cancer Minimal Residual Disease Testing Revenue Market Share by Manufacturers (2019-2025)
3.3 Cancer Minimal Residual Disease Testing Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.4 Global Cancer Minimal Residual Disease Testing Average Price by Manufacturers (2019-2025)
3.5 Manufacturers Cancer Minimal Residual Disease Testing Sales Sites, Area Served, Product Type
3.6 Cancer Minimal Residual Disease Testing Market Competitive Situation and Trends
3.6.1 Cancer Minimal Residual Disease Testing Market Concentration Rate
3.6.2 Global 5 and 10 Largest Cancer Minimal Residual Disease Testing Players Market Share by Revenue
3.6.3 Mergers & Acquisitions, Expansion
4 Cancer Minimal Residual Disease Testing Industry Chain Analysis
4.1 Cancer Minimal Residual Disease Testing Industry Chain Analysis
4.2 Market Overview of Key Raw Materials
4.3 Midstream Market Analysis
4.4 Downstream Customer Analysis
5 The Development and Dynamics of Cancer Minimal Residual Disease Testing Market
5.1 Key Development Trends
5.2 Driving Factors
5.3 Market Challenges
5.4 Market Restraints
5.5 Industry News
5.5.1 New Product Developments
5.5.2 Mergers & Acquisitions
5.5.3 Expansions
5.5.4 Collaboration/Supply Contracts
5.6 Industry Policies
6 Cancer Minimal Residual Disease Testing Market Segmentation by Type
6.1 Evaluation Matrix of Segment Market Development Potential (Type)
6.2 Global Cancer Minimal Residual Disease Testing Sales Market Share by Type (2019-2025)
6.3 Global Cancer Minimal Residual Disease Testing Market Size Market Share by Type (2019-2025)
6.4 Global Cancer Minimal Residual Disease Testing Price by Type (2019-2025)
7 Cancer Minimal Residual Disease Testing Market Segmentation by Application
7.1 Evaluation Matrix of Segment Market Development Potential (Application)
7.2 Global Cancer Minimal Residual Disease Testing Market Sales by Application (2019-2025)
7.3 Global Cancer Minimal Residual Disease Testing Market Size (M USD) by Application (2019-2025)
7.4 Global Cancer Minimal Residual Disease Testing Sales Growth Rate by Application (2019-2025)
8 Cancer Minimal Residual Disease Testing Market Consumption by Region
8.1 Global Cancer Minimal Residual Disease Testing Sales by Region
8.1.1 Global Cancer Minimal Residual Disease Testing Sales by Region
8.1.2 Global Cancer Minimal Residual Disease Testing Sales Market Share by Region
8.2 North America
8.2.1 North America Cancer Minimal Residual Disease Testing Sales by Country
8.2.2 U.S.
8.2.3 Canada
8.2.4 Mexico
8.3 Europe
8.3.1 Europe Cancer Minimal Residual Disease Testing Sales by Country
8.3.2 Germany
8.3.3 France
8.3.4 U.K.
8.3.5 Italy
8.3.6 Russia
8.4 Asia Pacific
8.4.1 Asia Pacific Cancer Minimal Residual Disease Testing Sales by Region
8.4.2 China
8.4.3 Japan
8.4.4 South Korea
8.4.5 India
8.4.6 Southeast Asia
8.5 South America
8.5.1 South America Cancer Minimal Residual Disease Testing Sales by Country
8.5.2 Brazil
8.5.3 Argentina
8.5.4 Columbia
8.6 Middle East and Africa
8.6.1 Middle East and Africa Cancer Minimal Residual Disease Testing Sales by Region
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Egypt
8.6.5 Nigeria
8.6.6 South Africa
9 Cancer Minimal Residual Disease Testing Market Production by Region
9.1 Global Production of Cancer Minimal Residual Disease Testing by Region (2019-2025)
9.2 Global Cancer Minimal Residual Disease Testing Revenue Market Share by Region (2019-2025)
9.3 Global Cancer Minimal Residual Disease Testing Production, Revenue, Price and Gross Margin (2019-2025)
9.4 North America Cancer Minimal Residual Disease Testing Production
9.4.1 North America Cancer Minimal Residual Disease Testing Production Growth Rate (2019-2025)
9.4.2 North America Cancer Minimal Residual Disease Testing Production, Revenue, Price and Gross Margin (2019-2025)
9.5 Europe Cancer Minimal Residual Disease Testing Production
9.5.1 Europe Cancer Minimal Residual Disease Testing Production Growth Rate (2019-2025)
9.5.2 Europe Cancer Minimal Residual Disease Testing Production, Revenue, Price and Gross Margin (2019-2025)
9.6 Japan Cancer Minimal Residual Disease Testing Production (2019-2025)
9.6.1 Japan Cancer Minimal Residual Disease Testing Production Growth Rate (2019-2025)
9.6.2 Japan Cancer Minimal Residual Disease Testing Production, Revenue, Price and Gross Margin (2019-2025)
9.7 China Cancer Minimal Residual Disease Testing Production (2019-2025)
9.7.1 China Cancer Minimal Residual Disease Testing Production Growth Rate (2019-2025)
9.7.2 China Cancer Minimal Residual Disease Testing Production, Revenue, Price and Gross Margin (2019-2025)
10 Key Companies Profile
10.1 Adaptive Biotechnologies Corporation
10.1.1 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Basic Information
10.1.2 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Product Overview
10.1.3 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing Product Market Performance
10.1.4 Adaptive Biotechnologies Corporation Business Overview
10.1.5 Adaptive Biotechnologies Corporation Cancer Minimal Residual Disease Testing SWOT Analysis
10.1.6 Adaptive Biotechnologies Corporation Recent Developments
10.2 ArcherDX
10.2.1 ArcherDX Cancer Minimal Residual Disease Testing Basic Information
10.2.2 ArcherDX Cancer Minimal Residual Disease Testing Product Overview
10.2.3 ArcherDX Cancer Minimal Residual Disease Testing Product Market Performance
10.2.4 ArcherDX Business Overview
10.2.5 ArcherDX Cancer Minimal Residual Disease Testing SWOT Analysis
10.2.6 ArcherDX Recent Developments
10.3 Inc. (Invitae Corporation)
10.3.1 Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Basic Information
10.3.2 Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Product Overview
10.3.3 Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing Product Market Performance
10.3.4 Inc. (Invitae Corporation) Cancer Minimal Residual Disease Testing SWOT Analysis
10.3.5 Inc. (Invitae Corporation) Business Overview
10.3.6 Inc. (Invitae Corporation) Recent Developments
10.4 Asuragen
10.4.1 Asuragen Cancer Minimal Residual Disease Testing Basic Information
10.4.2 Asuragen Cancer Minimal Residual Disease Testing Product Overview
10.4.3 Asuragen Cancer Minimal Residual Disease Testing Product Market Performance
10.4.4 Asuragen Business Overview
10.4.5 Asuragen Recent Developments
10.5 Arup Laboratories
10.5.1 Arup Laboratories Cancer Minimal Residual Disease Testing Basic Information
10.5.2 Arup Laboratories Cancer Minimal Residual Disease Testing Product Overview
10.5.3 Arup Laboratories Cancer Minimal Residual Disease Testing Product Market Performance
10.5.4 Arup Laboratories Business Overview
10.5.5 Arup Laboratories Recent Developments
10.6 Bio-Rad Laboratories
10.6.1 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Basic Information
10.6.2 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Product Overview
10.6.3 Bio-Rad Laboratories Cancer Minimal Residual Disease Testing Product Market Performance
10.6.4 Bio-Rad Laboratories Business Overview
10.6.5 Bio-Rad Laboratories Recent Developments
10.7 Cergentis B.V.
10.7.1 Cergentis B.V. Cancer Minimal Residual Disease Testing Basic Information
10.7.2 Cergentis B.V. Cancer Minimal Residual Disease Testing Product Overview
10.7.3 Cergentis B.V. Cancer Minimal Residual Disease Testing Product Market Performance
10.7.4 Cergentis B.V. Business Overview
10.7.5 Cergentis B.V. Recent Developments
10.8 F. Hoffmann- La Roche Ltd
10.8.1 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Basic Information
10.8.2 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Product Overview
10.8.3 F. Hoffmann- La Roche Ltd Cancer Minimal Residual Disease Testing Product Market Performance
10.8.4 F. Hoffmann- La Roche Ltd Business Overview
10.8.5 F. Hoffmann- La Roche Ltd Recent Developments
10.9 Guardant Health
10.9.1 Guardant Health Cancer Minimal Residual Disease Testing Basic Information
10.9.2 Guardant Health Cancer Minimal Residual Disease Testing Product Overview
10.9.3 Guardant Health Cancer Minimal Residual Disease Testing Product Market Performance
10.9.4 Guardant Health Business Overview
10.9.5 Guardant Health Recent Developments
10.10 ICON plc
10.10.1 ICON plc Cancer Minimal Residual Disease Testing Basic Information
10.10.2 ICON plc Cancer Minimal Residual Disease Testing Product Overview
10.10.3 ICON plc Cancer Minimal Residual Disease Testing Product Market Performance
10.10.4 ICON plc Business Overview
10.10.5 ICON plc Recent Developments
10.11 Invivoscribe
10.11.1 Invivoscribe Cancer Minimal Residual Disease Testing Basic Information
10.11.2 Invivoscribe Cancer Minimal Residual Disease Testing Product Overview
10.11.3 Invivoscribe Cancer Minimal Residual Disease Testing Product Market Performance
10.11.4 Invivoscribe Business Overview
10.11.5 Invivoscribe Recent Developments
10.12 Laboratory Corporation of America Holdings
10.12.1 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Basic Information
10.12.2 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Product Overview
10.12.3 Laboratory Corporation of America Holdings Cancer Minimal Residual Disease Testing Product Market Performance
10.12.4 Laboratory Corporation of America Holdings Business Overview
10.12.5 Laboratory Corporation of America Holdings Recent Developments
10.13 Mission Bio
10.13.1 Mission Bio Cancer Minimal Residual Disease Testing Basic Information
10.13.2 Mission Bio Cancer Minimal Residual Disease Testing Product Overview
10.13.3 Mission Bio Cancer Minimal Residual Disease Testing Product Market Performance
10.13.4 Mission Bio Business Overview
10.13.5 Mission Bio Recent Developments
10.14 Natera
10.14.1 Natera Cancer Minimal Residual Disease Testing Basic Information
10.14.2 Natera Cancer Minimal Residual Disease Testing Product Overview
10.14.3 Natera Cancer Minimal Residual Disease Testing Product Market Performance
10.14.4 Natera Business Overview
10.14.5 Natera Recent Developments
10.15 Inc.
10.15.1 Inc. Cancer Minimal Residual Disease Testing Basic Information
10.15.2 Inc. Cancer Minimal Residual Disease Testing Product Overview
10.15.3 Inc. Cancer Minimal Residual Disease Testing Product Market Performance
10.15.4 Inc. Business Overview
10.15.5 Inc. Recent Developments
10.16 NeoGenomics Laboratories
10.16.1 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Basic Information
10.16.2 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Product Overview
10.16.3 NeoGenomics Laboratories Cancer Minimal Residual Disease Testing Product Market Performance
10.16.4 NeoGenomics Laboratories Business Overview
10.16.5 NeoGenomics Laboratories Recent Developments
10.17 Opko Health
10.17.1 Opko Health Cancer Minimal Residual Disease Testing Basic Information
10.17.2 Opko Health Cancer Minimal Residual Disease Testing Product Overview
10.17.3 Opko Health Cancer Minimal Residual Disease Testing Product Market Performance
10.17.4 Opko Health Business Overview
10.17.5 Opko Health Recent Developments
10.18 Quest Diagnostics Incorporated
10.18.1 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Basic Information
10.18.2 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Product Overview
10.18.3 Quest Diagnostics Incorporated Cancer Minimal Residual Disease Testing Product Market Performance
10.18.4 Quest Diagnostics Incorporated Business Overview
10.18.5 Quest Diagnostics Incorporated Recent Developments
10.19 Sysmex Corporation
10.19.1 Sysmex Corporation Cancer Minimal Residual Disease Testing Basic Information
10.19.2 Sysmex Corporation Cancer Minimal Residual Disease Testing Product Overview
10.19.3 Sysmex Corporation Cancer Minimal Residual Disease Testing Product Market Performance
10.19.4 Sysmex Corporation Business Overview
10.19.5 Sysmex Corporation Recent Developments
10.20 Genetron Health
10.20.1 Genetron Health Cancer Minimal Residual Disease Testing Basic Information
10.20.2 Genetron Health Cancer Minimal Residual Disease Testing Product Overview
10.20.3 Genetron Health Cancer Minimal Residual Disease Testing Product Market Performance
10.20.4 Genetron Health Business Overview
10.20.5 Genetron Health Recent Developments
11 Cancer Minimal Residual Disease Testing Market Forecast by Region
11.1 Global Cancer Minimal Residual Disease Testing Market Size Forecast
11.2 Global Cancer Minimal Residual Disease Testing Market Forecast by Region
11.2.1 North America Market Size Forecast by Country
11.2.2 Europe Cancer Minimal Residual Disease Testing Market Size Forecast by Country
11.2.3 Asia Pacific Cancer Minimal Residual Disease Testing Market Size Forecast by Region
11.2.4 South America Cancer Minimal Residual Disease Testing Market Size Forecast by Country
11.2.5 Middle East and Africa Forecasted Consumption of Cancer Minimal Residual Disease Testing by Country
12 Forecast Market by Type and by Application (2025-2032)
12.1 Global Cancer Minimal Residual Disease Testing Market Forecast by Type (2025-2032)
12.1.1 Global Forecasted Sales of Cancer Minimal Residual Disease Testing by Type (2025-2032)
12.1.2 Global Cancer Minimal Residual Disease Testing Market Size Forecast by Type (2025-2032)
12.1.3 Global Forecasted Price of Cancer Minimal Residual Disease Testing by Type (2025-2032)
12.2 Global Cancer Minimal Residual Disease Testing Market Forecast by Application (2025-2032)
12.2.1 Global Cancer Minimal Residual Disease Testing Sales (K Units) Forecast by Application
12.2.2 Global Cancer Minimal Residual Disease Testing Market Size (M USD) Forecast by Application (2025-2032)
13 Conclusion and Key Findings
